免费获得国外相关药品，最快 1 个工作日回馈药物信息
出境医 / 临床实验 / A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
Study Description
Brief Summary:
This project is intended to provide CAR-T cell therapy products for patients with severely life-threatening relapsed and refractory hematological malignancies. These patients have been previously treated sufficiently, currently have no other treatment methods available, and do not meet the inclusion criteria of other clinical trial projects in the process of subject recruitment or meet their exclusion criteria. This project is designed to meet the urgent clinical needs of individual patients.
| Condition or disease | Intervention/treatment |
|---|---|
| Relapsed and Refractory Hematological Malignancies | Biological: CAR-T cells |
Study Design
| Study Type : | Expanded Access |
| Official Title: | A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies |
Arms and Interventions
Outcome Measures
Eligibility Criteria
Contacts and Locations
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date | July 1, 2019 | ||||
| First Posted Date | July 5, 2019 | ||||
| Last Update Posted Date | February 10, 2021 | ||||
| Descriptive Information | |||||
| Brief Title | A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies | ||||
| Brief Summary | This project is intended to provide CAR-T cell therapy products for patients with severely life-threatening relapsed and refractory hematological malignancies. These patients have been previously treated sufficiently, currently have no other treatment methods available, and do not meet the inclusion criteria of other clinical trial projects in the process of subject recruitment or meet their exclusion criteria. This project is designed to meet the urgent clinical needs of individual patients. | ||||
| Detailed Description | Not Provided | ||||
| Study Type | Expanded Access | ||||
| Intervention | Biological: CAR-T cells
Chimeric Antigen Receptor-T cells
|
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Expanded Access Status | Available | ||||
| Contacts |
|
||||
| Listed Location Countries | China | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT04008524 | ||||
| Responsible Party | wang, jianxiang, Institute of Hematology & Blood Diseases Hospital | ||||
| Study Sponsor | Institute of Hematology & Blood Diseases Hospital | ||||
| Collaborators | Juventas Cell Therapy Ltd. | ||||
| Investigators | Not Provided | ||||
| PRS Account | Institute of Hematology & Blood Diseases Hospital | ||||
| Verification Date | February 2021 | ||||
